Ocata Therapeutics Successfully Completes Dosing In Phase 1/2 RPE Studies

Ocata Therapeutics, Inc. , a leader in the field of regenerative ophthalmology, today announced that the company has completed dosing of its Phase 1/2 studies for dry age-related macular degeneration and Stargardt's Macular Degeneration . A total of 38 patients have been safely dosed.

http://ift.tt/1NEMGsJ